Inhibrx Biosciences, Inc. (INBX) Financials
All currency values in $ millions unless otherwise noted
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | $1 | $1 | $0 | $2 |
| General & Administrative | $26 | $23 | $128 | $29 |
| Research & Development | $100 | $113 | $204 | $192 |
| Total Operating Expenses | $126 | $136 | $332 | $221 |
| Operating Income | -$124 | -$135 | -$331 | -$219 |
| Non-Operating | ||||
| Net Interest Expense | -$15 | -$12 | -$13 | -$32 |
| Other Non-Operating Income (Expense) | $6 | $7 | $2,033 | $11 |
| EBT (Earnings Before Tax) | -$133 | -$140 | $1,688 | -$240 |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | ||||
| Net Income | -$133 | -$140 | $1,688 | -$241 |
| Per Share Data | ||||
| Revenue Per Share | $0.08 | $0.08 | $0.01 | $0.15 |
| EPS (Basic) | -$8.58 | -$9.04 | $114.01 | -$20.48 |
| EPS (Diluted) | -$8.58 | -$9.04 | $112.62 | -$20.48 |
| Weighted Avg Shares (Basic) | 15.7M | 15.5M | 14.8M | 11.8M |
| Weighted Avg Shares (Diluted) | 15.7M | 15.5M | 15.0M | 11.8M |
| Shares Outstanding | 15.7M | 15.5M | 15.0M | 11.8M |
Inhibrx Biosciences (INBX) financials: revenue, profit and margins
Inhibrx Biosciences (INBX) generated about n/a in revenue and -$138 million in net income (a -10,773.5% net margin) over the trailing twelve months, growing at roughly -15.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Inhibrx Biosciences profitable?+
Inhibrx Biosciences reported about -$138 million in net loss over the trailing twelve months, a net margin of roughly -10,773.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Inhibrx Biosciences's profit margins?+
Inhibrx Biosciences runs an operating margin of about -10,386.5%, a net margin of about -10,773.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Inhibrx Biosciences growing?+
Inhibrx Biosciences's revenue has compounded at roughly -15.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside INBX's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Related stocks: Biological Products, (No Diagnostic Substances)
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.